Dimensional Fund Advisors LP Cuts Position in Evolent Health, Inc. (NYSE:EVH)

Dimensional Fund Advisors LP decreased its stake in Evolent Health, Inc. (NYSE:EVHGet Rating) by 0.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,301,401 shares of the technology company’s stock after selling 5,868 shares during the period. Dimensional Fund Advisors LP owned approximately 3.69% of Evolent Health worth $91,349,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Granahan Investment Management Inc. MA lifted its stake in shares of Evolent Health by 1.0% in the third quarter. Granahan Investment Management Inc. MA now owns 4,813,553 shares of the technology company’s stock valued at $149,220,000 after purchasing an additional 45,567 shares during the period. Rock Springs Capital Management LP lifted its stake in shares of Evolent Health by 10.4% in the third quarter. Rock Springs Capital Management LP now owns 1,875,000 shares of the technology company’s stock valued at $58,125,000 after purchasing an additional 175,957 shares during the period. Geode Capital Management LLC lifted its stake in shares of Evolent Health by 1.6% in the third quarter. Geode Capital Management LLC now owns 1,316,570 shares of the technology company’s stock valued at $40,813,000 after purchasing an additional 20,837 shares during the period. Northern Trust Corp lifted its stake in shares of Evolent Health by 0.8% in the fourth quarter. Northern Trust Corp now owns 994,717 shares of the technology company’s stock valued at $27,524,000 after purchasing an additional 7,563 shares during the period. Finally, Kornitzer Capital Management Inc. KS acquired a new stake in shares of Evolent Health in the fourth quarter valued at about $14,833,000. Hedge funds and other institutional investors own 93.27% of the company’s stock.

Several analysts have issued reports on EVH shares. Zacks Investment Research raised shares of Evolent Health from a “hold” rating to a “buy” rating and set a $32.00 price target on the stock in a report on Wednesday, May 4th. Canaccord Genuity Group upped their price target on shares of Evolent Health from $40.00 to $45.00 in a report on Monday, May 9th. Guggenheim began coverage on shares of Evolent Health in a report on Tuesday, March 29th. They issued a “buy” rating and a $43.00 price target on the stock. Piper Sandler cut their price target on Evolent Health from $36.00 to $32.00 in a report on Thursday, February 24th. Finally, BTIG Research boosted their price target on Evolent Health from $35.00 to $40.00 and gave the stock a “buy” rating in a report on Friday, March 25th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $39.86.

NYSE EVH opened at $27.97 on Friday. The business’s 50-day moving average price is $29.58 and its 200 day moving average price is $27.32. The company has a current ratio of 1.21, a quick ratio of 1.21 and a debt-to-equity ratio of 0.46. Evolent Health, Inc. has a twelve month low of $18.33 and a twelve month high of $34.60. The company has a market capitalization of $2.54 billion, a PE ratio of -73.61 and a beta of 2.07.

Evolent Health (NYSE:EVHGet Rating) last announced its quarterly earnings data on Wednesday, May 4th. The technology company reported $0.12 earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.20. The business had revenue of $297.10 million for the quarter, compared to analyst estimates of $286.81 million. Evolent Health had a negative net margin of 3.35% and a negative return on equity of 0.86%. The company’s revenue was up 37.7% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.06) EPS. Equities analysts predict that Evolent Health, Inc. will post -0.21 EPS for the current year.

In other news, COO Steve Tutewohl sold 1,918 shares of the stock in a transaction on Thursday, March 3rd. The shares were sold at an average price of $27.30, for a total value of $52,361.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Frank J. Williams sold 20,000 shares of the firm’s stock in a transaction on Thursday, February 17th. The shares were sold at an average price of $23.70, for a total transaction of $474,000.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 27,306 shares of company stock valued at $674,046. Insiders own 4.20% of the company’s stock.

About Evolent Health (Get Rating)

Evolent Health, Inc, a healthcare company, through its subsidiary, Evolent Health LLC, provides clinical and administrative solutions to payers and providers in the United States. It operates in two segments, Evolent Health Services and Clinical Solutions. The Evolent Health Services segment provides an integrated administrative and clinical platform for health plan administration and population health management.

Recommended Stories

Want to see what other hedge funds are holding EVH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Evolent Health, Inc. (NYSE:EVHGet Rating).

Institutional Ownership by Quarter for Evolent Health (NYSE:EVH)

Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.